Our top pick for
24/5 trading
Abbott Laboratories is a medical devices business with stocks listed in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$117.13 – an increase of 1.2% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
24/5 trading
Our top pick for
Copy trading
Our top pick for
Mobile app
Abbott Laboratories's shares were split on a 10000:4798 basis on 1 January 2013. So if you had owned 4798 shares the day before the split, the next day you would own 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.
52-week range | US$97.0095 - US$121 |
---|---|
50-day moving average | US$115.493 |
200-day moving average | US$110.7163 |
Target price | US$129.6579 |
PE ratio | 34.9635 |
Dividend yield | US$2.2 (1.91%) |
Earnings per share (TTM) | US$3.29 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $117.13
1 week (2024-11-13) | 1.20% |
---|---|
1 month (2024-10-21) | 0.12% |
3 months (2024-08-20) | 5.74% |
6 months (2024-05-20) | 13.49% |
1 year (2023-11-20) | 15.74% |
---|---|
2 years (2022-11-18) | 12.77% |
3 years (2021-11-19) | -7.66% |
5 years (2019-11-20) | 39.62% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as US$97.0095 up to US$121. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.722. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).
Revenue TTM | US$41.2 billion |
---|---|
Operating margin TTM | 18.75% |
Gross profit TTM | US$24.6 billion |
Return on assets TTM | 6.49% |
Return on equity TTM | 14.84% |
Profit margin | 13.99% |
Book value | 22.944 |
Market capitalisation | US$199.5 billion |
EBITDA | US$10.8 billion |
TTM: trailing 12 months
Dividend payout ratio: 48.67% of net profits
Recently Abbott Laboratories has paid out, on average, around 48.67% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.91% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.91% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $2.2 per share.
While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.
Abbott Laboratories's most recent dividend payout was on 14 November 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 October 2024 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 32.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 12/31/2018) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.98/100
Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 20.71/100
Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.15/100
Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.
Abbott Laboratories was last rated for ESG on: 2019-01-01.
Total ESG score | 32.35 |
---|---|
Total ESG percentile | 60.66 |
Environmental score | 3.98 |
Environmental score percentile | 5 |
Social score | 20.71 |
Social score percentile | 5 |
Governance score | 13.15 |
Governance score percentile | 5 |
Level of controversy | 3 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
CHESS sponsorship allows you to directly own ASX listed shares in your own name, but it comes with some drawbacks. Find out if it's right for you.
Big gainers included SelfWealth, Metal Hawk and Island Pharmaceuticals.
Top gainers included PYC Therapeutics, Fineos Corporation Holdings and Weebit Nano.
A wealth management company that will appeal to ESG investors.
Find out the different ways you can invest in the S&P 500 index from Australia.
Index funds are a hot topic right now, but how do you actually invest in them?
Join the world’s largest social trading network and learn from experienced forex traders with eToro Australia.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Follow these tips to find the best share trading platform for you.
Learn everything you need to know in this easy to follow, step-by-step guide to buying shares in Australia.